|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comprehensive risk assessment, including calculation of life-time ASCVD risk, as well as incorporating non-traditional risk factors including lipoprotein (a), strong family history of premature ASCVD, familial hypercholesterolemia, LDL-C level and presence of underlying systemic inflammatory disorders can be helpful in identifying young adults who stand to benefit the most from statin therapy.
|
30808553 |
2020 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Elevated lipoprotein(a) (Lp(a)) levels are associated with increased risk for atherosclerotic cardiovascular disease (ASCVD).
|
29550494 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low-density lipoprotein cholesterol (LDL-C) level and lipoprotein(a) [Lp(a)] ≥ 50 mg/dL predict atherosclerotic cardiovascular disease (ASCVD) risk in adults with familial hypercholesterolemia (FH), but their role for children with FH is less clear.
|
30150142 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It is reasonable to measure Lp(a) levels to reclassify ASCVD risk and manage individuals with elevated Lp(a) to further reduce the residual risk of ASCVD, especially with IONIS-APO(a)-L<sub>RX</sub>.
|
31655942 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this review is to highlight our emerging understanding of lipoprotein(a) [Lp(a)]'s role in atherosclerotic cardiovascular disease (ASCVD), its structure-function relationship, and promising developments within the therapeutic pipeline.
|
31261178 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Non-high-density (HDL)-cholesterol, low-density lipoprotein (LDL)-particle number, apolipoprotein B, lipoprotein(a) (Lp(a)), and small-dense (sdLDL) and large-buoyant (lbLDL) LDL-subfractions are emerging apo B-containing atherosclerotic cardiovascular disease (ASCVD) risk factors.
|
31311555 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interest in lipoprotein (a) [Lp(a)] has exploded over the past decade with the emergence of genetic and epidemiological studies pinpointing elevated levels of this unique lipoprotein as a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD).
|
30732864 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Major atherosclerotic cardiovascular event (MACE) prevention among the highest risk patients with ASCVD requires aggressive management of global risks, including lowering of the fundamental atherogenic apolipoprotein B-associated lipoprotein cholesterol particles [i.e., triglyceride-rich lipoprotein remnant cholesterol, low-density lipoprotein cholesterol (LDL-C), and lipoprotein(a)].
|
31754844 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, in regard to lipoprotein(a)-which is a strong risk factor for ASCVD-there are exciting developments in the therapeutic pipeline which reduce circulating lipoprotein(a) levels by nearly 90%.
|
31378838 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) and elevated lipoprotein(a) [Lp(a)] are inherited disorders associated with premature atherosclerotic cardiovascular disease (ASCVD).
|
30846097 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, a cohort of 110 patients with established atherosclerotic cardiovascular disease (ASCVD) due to hypercholesterolemia or concomitant lipoprotein(a)-hyperlipoproteinemia, who received PCSK9 antibodies for the first time during routine care, were consecutively identified.
|
30817043 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is no data to indicate whether mipomersen, lomitapide, or IONIS-APO(a)-LRx decrease ASCVD events and mortality.
|
30847681 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this biracial cohort, elevated lipoprotein(a) levels in Caucasian individuals with diabetes or prediabetes were associated with further increased ASCVD risk.
|
30685442 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, existing lipid-lowering drugs have little impact on lipoprotein(a) (Lp(a)) or plasma triglycerides, two other risk factors for ASCVD.
|
31340607 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oxidized phospholipids, which modify Lp(a) primarily by covalent binding to its unique apolipoprotein(a) (apo(a)) component, might hold the key to Lp(a) pathogenicity and provide a mechanistic link between ASCVD and CAVD.
|
30675027 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although a major determinant of ASCVD event reduction is the absolute change of low-density lipoprotein-cholesterol (LDL-C), considerable residual risk remains and new therapeutic options are required, in particular, to address triglyceride-rich lipoproteins and lipoprotein(a) [Lp(a)].
|
31449975 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although lipoprotein(a) (Lp(a)) has been regarded as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), its predictive role in outcomes in stable coronary artery disease (CAD) has been undetermined.
|
31178022 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)], discovered in 1963, has been associated with atherosclerotic cardiovascular disease (ASCVD) independent of other traditional risk factors, including LDL cholesterol.
|
31061262 |
2019 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent data have suggested an important role of lipoprotein (a) [Lp(a)] and proprotein convertase substilisin/kexin type 9 (PCSK9) in the development of atherosclerotic cardiovascular disease (ASCVD) in both general population and family hypercholesterolemia (FH), while the relation of Lp(a) to PCSK9 has not been examined.
|
29129821 |
2018 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Age, male sex, history of previous ASCVD, high blood pressure, increased body mass index, active smoking, and low-density lipoprotein cholesterol and lipoprotein(a) levels were independent predictors of incident ASCVD from which a risk equation with a Harrell C index of 0.85 was derived.
|
28275165 |
2017 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous ASCVD events, elevated blood lipoprotein(a), cutaneous markers of cholesterol deposit are among other factors that indicate a higher ASCVD risk in familial hypercholesterolemia individuals underlying a more severe form of the phenotype.
|
28059950 |
2017 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Age, male sex, increased body mass index, hypertension, type 2 diabetes mellitus, smoking habit, and lipoprotein(a) >50 mg/dL were independently associated to ASCVD.
|
27444203 |
2016 |
|
Arteriosclerotic cardiovascular disease, NOS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The former was only present in 2 of the 100 subjects studied, was associated with a lysine-binding defective lipoprotein(a) [Lp(a)], low plasma levels of Lp(a), and no evidence of atherosclerotic cardiovascular disease (ASCVD).
|
7863976 |
1995 |